NI200900131A - Compuesto de [1,2,3]-benzotriazinona-3-. sustituid - Google Patents
Compuesto de [1,2,3]-benzotriazinona-3-. sustituidInfo
- Publication number
- NI200900131A NI200900131A NI200900131A NI200900131A NI200900131A NI 200900131 A NI200900131 A NI 200900131A NI 200900131 A NI200900131 A NI 200900131A NI 200900131 A NI200900131 A NI 200900131A NI 200900131 A NI200900131 A NI 200900131A
- Authority
- NI
- Nicaragua
- Prior art keywords
- treatment
- compound
- brain
- relates
- benzotriazinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta invención se refiere a la prevención y tratamiento de insuficiencia cerebral, incluyendo incremento del funcionamiento de receptores en las sinapsis en las redes cerebrales responsables de comportamiento de orden superior. Estas redes cerebrales están implicadas en las capacidades cognitivas relacionadas con la alteración de la memoria, tal como se observa en una variedad de demencias, y en desequilibrios de la actividad neuronal entre diferentes regiones cerebrales, como se sugiere en trastornos tales como la enfermedad de Parkinson, esquizofrenia y trastornos afectivos. En un aspecto particular, la presente invención se refiere a un compuesto útil para el tratamiento de dichas condiciones, y a métodos para utilizar este compuesto para dicho tratamiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87850307P | 2007-01-03 | 2007-01-03 | |
| US92143307P | 2007-04-02 | 2007-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI200900131A true NI200900131A (es) | 2010-03-11 |
Family
ID=39608956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI200900131A NI200900131A (es) | 2007-01-03 | 2009-07-01 | Compuesto de [1,2,3]-benzotriazinona-3-. sustituid |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8173644B2 (es) |
| EP (1) | EP2144506B1 (es) |
| JP (1) | JP5139446B2 (es) |
| CN (1) | CN101616592B (es) |
| AP (1) | AP2502A (es) |
| AR (1) | AR064740A1 (es) |
| AT (1) | ATE527269T1 (es) |
| AU (1) | AU2007342365B2 (es) |
| BR (1) | BRPI0720749A2 (es) |
| CA (1) | CA2674460C (es) |
| CR (1) | CR10906A (es) |
| CU (1) | CU23804B7 (es) |
| CY (1) | CY1112493T1 (es) |
| DK (1) | DK2144506T3 (es) |
| EA (1) | EA017437B1 (es) |
| EC (1) | ECSP099499A (es) |
| ES (1) | ES2374995T3 (es) |
| GE (1) | GEP20125438B (es) |
| GT (1) | GT200900189A (es) |
| HK (1) | HK1140105A1 (es) |
| HN (1) | HN2009001268A (es) |
| HR (1) | HRP20110970T1 (es) |
| IL (1) | IL199651A (es) |
| MA (1) | MA31160B1 (es) |
| ME (1) | ME00819B (es) |
| MX (1) | MX2009007242A (es) |
| MY (1) | MY154877A (es) |
| NI (1) | NI200900131A (es) |
| NZ (1) | NZ578293A (es) |
| PL (1) | PL2144506T3 (es) |
| PT (1) | PT2144506E (es) |
| RS (1) | RS52108B (es) |
| SG (1) | SG163545A1 (es) |
| SI (1) | SI2144506T1 (es) |
| SV (1) | SV2009003322A (es) |
| TN (1) | TN2009000277A1 (es) |
| WO (1) | WO2008085506A1 (es) |
| ZA (1) | ZA200904826B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009007209A (es) * | 2007-01-03 | 2009-10-12 | Cortex Pharma Inc | Compuestos de [1, 2, 3]-benzotriazinona-sustituidos en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. |
| KR101599661B1 (ko) | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
| US8119632B2 (en) | 2007-08-10 | 2012-02-21 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
| US8263591B2 (en) | 2007-08-10 | 2012-09-11 | Cortex Pharmaceuticals, Inc. | Bicyclic amides for enhancing glutamatergic synaptic responses |
| US20110257186A1 (en) * | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
| EP2784065B1 (en) | 2011-11-22 | 2016-10-05 | Beijing Medisan Technology Co. Ltd. | Glycine reuptake inhibitor and use thereof |
| FR3019464B1 (fr) * | 2014-04-07 | 2016-05-06 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| FR3034019B1 (fr) | 2015-03-26 | 2017-03-17 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent |
| EP3313836B1 (en) | 2015-06-26 | 2020-11-11 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| CN106226509B (zh) * | 2016-08-12 | 2019-09-06 | 中国人民解放军第四军医大学 | 一种在小鼠前扣带回皮层诱发dse现象的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723436A (en) * | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| FR2597103B1 (fr) * | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
| CA2450801C (en) * | 1992-07-24 | 2009-11-17 | The Regent Of The University Of California | Drugs that enhance synaptic responses mediated by ampa receptors |
| US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
| DK0709384T3 (da) * | 1994-10-31 | 1999-08-23 | Merck Patent Gmbh | Benzylpiperidinderivater med høj affinitet til aminosyrereceptorers bindingssteder |
| US5650409A (en) * | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) * | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| AU4416197A (en) * | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US5985871A (en) * | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| EE200000468A (et) | 1998-02-18 | 2002-04-15 | Neurosearch A/S | Ühendid, nende kasutamine ja farmatseutiline kompositsioon |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6303542B1 (en) * | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
| PL371722A1 (en) * | 2001-11-26 | 2005-06-27 | Cortex Pharmaceuticals, Inc. | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses |
| JP2003238555A (ja) * | 2002-02-20 | 2003-08-27 | Sumitomo Pharmaceut Co Ltd | 細胞死抑制剤 |
| AUPS255202A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
| US20060276462A1 (en) * | 2003-01-13 | 2006-12-07 | Deadwyler Sam A | Method of treating cognitive decline due to sleep deprivation and stress |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| MX2009007209A (es) * | 2007-01-03 | 2009-10-12 | Cortex Pharma Inc | Compuestos de [1, 2, 3]-benzotriazinona-sustituidos en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. |
| KR101599661B1 (ko) * | 2007-05-17 | 2016-03-03 | 코텍스 파마슈티칼스, 인크. | 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물 |
| US8263591B2 (en) | 2007-08-10 | 2012-09-11 | Cortex Pharmaceuticals, Inc. | Bicyclic amides for enhancing glutamatergic synaptic responses |
| NZ584098A (en) * | 2007-09-20 | 2012-05-25 | Cortex Pharma Inc | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
-
2007
- 2007-12-28 PT PT07868093T patent/PT2144506E/pt unknown
- 2007-12-28 CA CA2674460A patent/CA2674460C/en not_active Expired - Fee Related
- 2007-12-28 BR BRPI0720749-2A patent/BRPI0720749A2/pt not_active Application Discontinuation
- 2007-12-28 AP AP2009004931A patent/AP2502A/xx active
- 2007-12-28 RS RS20110587A patent/RS52108B/en unknown
- 2007-12-28 PL PL07868093T patent/PL2144506T3/pl unknown
- 2007-12-28 CN CN2007800508375A patent/CN101616592B/zh not_active Expired - Fee Related
- 2007-12-28 JP JP2009544857A patent/JP5139446B2/ja not_active Expired - Fee Related
- 2007-12-28 EA EA200900925A patent/EA017437B1/ru not_active IP Right Cessation
- 2007-12-28 SG SG201004695-1A patent/SG163545A1/en unknown
- 2007-12-28 ME MEP-2009-238A patent/ME00819B/me unknown
- 2007-12-28 MX MX2009007242A patent/MX2009007242A/es active IP Right Grant
- 2007-12-28 US US12/448,784 patent/US8173644B2/en not_active Expired - Fee Related
- 2007-12-28 DK DK07868093.1T patent/DK2144506T3/da active
- 2007-12-28 WO PCT/US2007/026416 patent/WO2008085506A1/en active Application Filing
- 2007-12-28 SI SI200730806T patent/SI2144506T1/sl unknown
- 2007-12-28 NZ NZ578293A patent/NZ578293A/en not_active IP Right Cessation
- 2007-12-28 EP EP07868093A patent/EP2144506B1/en active Active
- 2007-12-28 AT AT07868093T patent/ATE527269T1/de active
- 2007-12-28 MY MYPI20092796A patent/MY154877A/en unknown
- 2007-12-28 GE GEAP200711384A patent/GEP20125438B/en unknown
- 2007-12-28 ES ES07868093T patent/ES2374995T3/es active Active
- 2007-12-28 ZA ZA200904826A patent/ZA200904826B/xx unknown
- 2007-12-28 AU AU2007342365A patent/AU2007342365B2/en not_active Ceased
-
2008
- 2008-01-03 AR ARP080100022A patent/AR064740A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 TN TNP2009000277A patent/TN2009000277A1/fr unknown
- 2009-07-01 NI NI200900131A patent/NI200900131A/es unknown
- 2009-07-02 IL IL199651A patent/IL199651A/en active IP Right Grant
- 2009-07-02 SV SV2009003322A patent/SV2009003322A/es unknown
- 2009-07-02 GT GT200900189A patent/GT200900189A/es unknown
- 2009-07-02 CR CR10906A patent/CR10906A/es not_active Application Discontinuation
- 2009-07-03 HN HN2009001268A patent/HN2009001268A/es unknown
- 2009-07-03 CU CU20090117A patent/CU23804B7/es active IP Right Grant
- 2009-07-07 EC EC2009009499A patent/ECSP099499A/es unknown
- 2009-07-31 MA MA32135A patent/MA31160B1/fr unknown
-
2010
- 2010-06-29 HK HK10106349.3A patent/HK1140105A1/xx not_active IP Right Cessation
-
2011
- 2011-12-23 HR HR20110970T patent/HRP20110970T1/hr unknown
- 2011-12-28 CY CY20111101287T patent/CY1112493T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI200900131A (es) | Compuesto de [1,2,3]-benzotriazinona-3-. sustituid | |
| TN2009000278A1 (en) | 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses | |
| CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
| CU20080044A7 (es) | Composiciones farmacéuticas para el tratamiento de trastornos del oído interno. | |
| CR20130339A (es) | Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos | |
| CL2007003879A1 (es) | Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson. | |
| ECSP10010226A (es) | Compuestos derivados de amina para tratar enfermedades y trastornos oftálmicos | |
| CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
| BRPI0810561A2 (pt) | métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13. | |
| ECSP10010230A (es) | Derivados de isoxazolo-piridina | |
| BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
| CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. | |
| BRPI0917440A2 (pt) | composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho | |
| WO2014037416A3 (en) | Compositions for treating parkinson's disease | |
| BRPI0811581A2 (pt) | Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos | |
| ECSP11010956A (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos | |
| WO2013029060A3 (en) | Compositions and methods for treating neurodegenerative disease | |
| ECSP088280A (es) | Compuestos de imidazol para el tratamiento de trastornos neurológicos | |
| WO2009093864A3 (ko) | 뇌질환의 예방 또는 치료용 조성물 | |
| IL196615A0 (en) | N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders | |
| DE602008004563D1 (de) | Carbonylamino-derivate zur behandlung von entzündlicher darmerkrankung | |
| WO2012068553A3 (en) | Methods of diagnosing and treating neurodegenerative diseases | |
| UA93306C2 (ru) | Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций | |
| CL2018001633A1 (es) | Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos | |
| EP2552473A4 (en) | METHOD FOR THE TREATMENT OF MORBUS PARKINSON AND OTHER DISORDERS OF DOPAMINERGIC NEURONS OF THE BRAIN |